問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Taipei Medical University Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • 110Taipei CitySin Yi

Recruiting Trial

241Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

444Cases

2025-06-01 - 2028-07-31

Phase III

Completed
An Open-Label Long-Term Phase III Extension Study to Assess the Long-Term Safety and Tolerability of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5)

  • Condition/Disease

    Severe Eosinophilic Asthma

  • Test Drug

    tablet

Participate Sites
3Sites

Recruiting3Sites

2023-09-01 - 2027-12-31

Phase I

Active
A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Food Effect and Potential Efficacy of PS1 in Human

  • Condition/Disease

    PS1

  • Test Drug

    tablet

Participate Sites
1Sites

Recruiting1Sites

2023-12-01 - 2026-12-31

Phase I/II

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
3Sites

Recruiting3Sites

2026-01-01 - 2032-03-10

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting8Sites

2010-01-01 - 2013-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2013-06-01 - 2016-01-31

Phase III

Completed
A Phase 3, Open Label, Randomized, Parallel, 26-Week Treatment Study Comparing LY2605541 with Insulin Glargine as Basal Insulin Treatment in Combination with Oral Anti-Hyperglycemia Medications in Asian Insulin Naïve Patients with Type 2 Diabetes Mellitus

  • Condition/Disease

    Type II DM

  • Test Drug

    (LY2605541)

Participate Sites
9Sites

Terminated9Sites

2024-02-27 - 2030-01-27

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting1Sites

Suspended15Sites

2025-09-30 - 2032-03-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2022-10-01 - 2027-12-31

Phase III

Active
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity

  • Condition/Disease

    Overweight

  • Test Drug

    Tirzepatide（LY3298176）

Participate Sites
11Sites

Not yet recruiting2Sites

Recruiting9Sites

2021-04-20 - 2024-07-02

Phase III

Completed
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT)

  • Condition/Disease

    Heart Failure with Preserved Ejection Fraction and Obesity

  • Test Drug

    Tirzepatide

Participate Sites
7Sites

Recruiting7Sites

1 19 20 21 22 23 45
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB